LSPN959

LSPN959 (0.049-50 μM; 72 h) potently inhibits chloroquine-sensitive Plasmodium falciparum 3D7 strain growth with an IC₅₀ of 1.05 μM, exhibits low cytotoxicity against human HepG2 and HEK293 cells, and has a high selectivity index of 95^[1].
LSPN959 (0.049-50 μM; 24-72 h) exhibits a slow-acting inhibitory profile against Plasmodium falciparum 3D7 strain, with IC₅₀ ratios and morphological observations consistent with delayed parasite killing and recovery potential post-exposure^[1].
LSPN959 (72 h)'s antiplasmodial activity against Plasmodium falciparum 3D7 strain is not reversed by IPP supplementation, indicating it does not inhibit apicoplast-dependent isoprenoid biosynthesis^[1].
LSPN959 (72 h) exhibits an additive interaction when combined with Artesunate against Plasmodium falciparum 3D7 strain, with no statistically significant synergy or antagonism observed^[1].
LSPN959 (0.049-50 μM; 72 h) retains potent antiplasmodial activity against multidrug-resistant Plasmodium falciparum strains (3D7^R_MMV848, Dd2R_DSM265, Dd2, K1, TM90C6B) with resistance indices close to 1, showing no cross-resistance with standard antimalarials^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.